Background Although recent large-scale clinical studies have shown that preoperative
Introduction
were evaluated in this study, and the severity of complications was defmed according to the Clavien-Dindo classification [22] . If more than one complication occurred in a single patient, the most severe grade was considered for the present analysis. In the present study, severe complication was defined as a complication of grade III or greater.
Pancreatic fistula was defmed according to the defmition of the International Study
Group on Pancreatic Fistula (ISGPF) [23] . We further evaluated various outcome parameters, including the length of postoperative hospital stay and prognosis. Date of last follow-up was August 2014.
Statistical analysis
The parameters were compared using the Student's t test, the chi-square test or Fisher's exact test as appropriate. Continuous variables were expressed as the mean and SD. The logistic regression model was used for multivariate analysis. All significant variables in the univariate analysis were entered into the multivariate analysis. Overall survival (OS) was calculated from the date of initial treatment with either surgery or neoadjuvant cancer therapy until death or last follow-up. The survival curve was estimated according to the Kaplan-Meier method, and differences were analyzed using the log-rank test. All reported P values were two-sided. A P value of< 0.05 was considered statistically significant and confidence intervals (Cl) were calculated at the 95% level. The statistical analyses were performed using the SPSS software program, version 19.0 (SPSS, Chicago, IL ).
Results

Cutoff value of eGFR
To determine the optimal cutoff value of eGFR to predict postoperative complications, we set and evaluated various values of eGFR (30-60 rnL/min/1. 73m 2 ) in relation to either any or severe complications. As a result, we defmed 55 as the cutoff value and classified all patients into either low or normal eGFR groups. This was also the same value determined by the receiver operating characteristic curve analysis. As a result, 219 patients (86.2%) with eGFR of 55 and higher were classified as the normal eGFR group, and 35 patients (13.8%) with eGFR of below 55 were classified as the low eGFR group (Fig. 1) . Among the low eGFR group, only 3 patients (8.6%) had eGFR of below 30 mL/min/1.73 m 2 .
Patient clinicopathological characteristics according to eGFR status
Patient characteristics of each group are summarized in Table 1 . The patients in the low eGFR group were significantly older than those in the normal group(?= 0.009). The patients in the low eGFR group had more preoperative comorbidities including renal disease (26% vs. 2%), respiratory disorder (14% vs. 5%), and cardiovascular disease (26% vs. 13%). While there were no differences in hemoglobin and albumin levels between two groups, serum creatinine level in the low eGFR group was significantly higher than that in the normal group (P < 0.001). The low eGFR group had soft pancreas more frequently compared to the normal group (P = 0.029). Finally, benign disease was significantly more common, while PDAC was significantly less common in the low eGFR group than in the normal group (P = 0.002). However, since our surgicai indication did not differ between patients with and without renal dysfunction, the reasons for these differences of original diseases are unknown.
Perioperative data
We then compared perioperative data between two groups (Table 2 ). There were no significant differences between two groups in operating time, intraoperative blood loss, and operative procedure, while blood transfusion was performed more often in the low eGFR group than in the normal group (P = 0.038).
Postoperative outcomes
In total, 183 patients (72%) developed postoperative complications (Table 3 ). The incidence was significantly higher in the low eGFR group than in the normal group (P = 0.003). Furthermore, grade B/C pancreatic fistula occurred more frequently in the low eGFR group compared to the normal group (P = 0.001). In addition, in patients with soft pancreas, the incidence of grade B/C pancreatic fistula in the low eGFR group is also higher than that in the normal group (P = 0.012). The grade B/C pancreatic fistula rates in patients with hard pancreas did not differ between two groups. On the other hand, there were no significant differences between groups in each type of complication, although there was a tendency toward an increase in the low eGFR group, especially for medical complication. Furthermore, the low eGFR group had more severe complications than the normal group (57.1% vs. 28.8%, P = 0.005).
Risk factors for severe complications
Next, we analyzed risk factors for severe postoperative complications after PD. In the univariate analysis, malignant disease other than PDAC, no neoadjuvant CRT, soft pancreas, operative time, and low eGFR were found to be significant in relation to the incidence of severe complications (Table 4 ). The multivariate analysis demonstrated that soft pancreas, operating time, and low GFR were independent risk factors for severe complications (soft pancreas: OR 2.527, 95% CI 1.282 to 4.982; P = 0.007, operating time: OR 1.006, 95% CI 1.002 to 1.009, P = 0.002, GFR: OR 2.898, 95% CI 1.341 to 6.262; P = 0.007).
Risk factors for clinically relevant pancreatic fistula
We further investigated risk factors for grade B/C pancreatic fistula. In the univariate analysis, malignant disease other than PDAC, no neoadjuvant CRT, soft pancreas, portal vein resection, and low eGFR were risk factors significantly associated with grade B/C pancreatic fistula (Table 5) . In multivariate analysis, eGFR as well as soft pancreas were independent risk factors for grade B/C pancreatic fistula ( eGFR: OR 2.609, 95% CI 1.116 to 6.098, P = 0.027, soft pancreas: OR 3.021, 95% CI 1.162 to 7.853, p = 0.023).
Postoperative survival Finally, we examined the impact of eGFR status on patient prognosis in each original have also demonstrated severe preoperative renal insufficiency as an independent risk factor associated with increased risk of morbidity after pancreatic resection, although the precise mechanisms are not yet known in any type of surgery [17, 18] . In those studies, the number of patients with such severe renal insufficiency including dialysis dependence was relatively small in the entire study population. In this study, we addressed whether patients with preoperative asymptomatic renal dysfunction might be at an increased risk for morbidity and mortality after PD. Accordingly, we found several important findings as described below.
First, there were significant correlations of low eGFR status with advanced age and preoperative comorbidities including renal disease, respiratory disorder, and cardiovascular disease, while there were no significant correlations between low eGFR status and perioperative variables except for blood transfusion. Although the precise reason for the difference in blood transfusion is unclear, the older age and higher comorbidity rate in patients of the low eGFR group might be related. Data suggest that asymptomatic renal dysfunction may represent patient frailty. Second, there were significant correlations of eGFR status with the incidence of morbidity, grade B/C pancreatic fistula, and severe complications. The data may be partly consistent with previous studies on severe renal insufficiency (17, 18] . In contrast, the previous study has shown that preoperative severe renal insufficiency was not associated with increased risk for pancreatic fistula in spite of the type of pancreatic resection [17] .
Although the reason for this discrepancy is not clear, we assumed that the increased risk for grade B/C pancreatic fistula in the low eGFR group was due to soft pancreas found more frequently in that group. However, even when analyzed in patients with soft pancreas, grade B/C pancreatic :fistula occurred more frequently in the low eGFR group compared to the normal group. Furthermore, multivariate analysis indicated that both low eGFR status and soft pancreas were significant independent risk factors for grade B/C pancreatic fistula as well as severe complications. Therefore, data suggest that asymptomatic renal dysfunction had a significant negative impact on clinically relevant postoperative complications after PD.
There are several potential underlying mechanisms for associations of asymptomatic renal dysfunction with increased morbidity after PD. First, the tissue vulnerability in patients with renal dysfunction may be related to increased complications. As described above, patients in the low eGFR group had advanced age and preoperative comorbidity such as cardiovascular disease or respiratory disorder more frequently than those in the Finally, we evaluated the impact of asymptomatic renal dysfunction on patient survival. Previous studies have shown that severe renal insufficiency was not related to mortality after pancreatic resection, while there are no reports to address overall survival after pancreatic resection in patients with severe renal insufficiency. Our data also indicated that asymptomatic renal dysfunction had no significant impact on mortality after PD. Furthermore, the results also demonstrated that asymptomatic renal dysfunction had no impact on patient prognosis, regardless of original disease pathology.
Taken together, PD may be justified for patients with renal dysfunction, even if there are increased risks of postoperative complications after PD.
To our best of knowledge, this is the first report to address the clinical impact of preoperative asymptomatic renal dysfunction on postoperative clinical course after PD.
Due to the retrospective nature and single-center experience, there are limitations to reach a definitive conclusion. In particular, the cut-off value of eGFR needs to be prospectively validated However, we should be aware that asymptomatic renal dysfunction may be a significant risk factor for severe morbidity and clinically relevant pancreatic fistula after PD. Although it had no impact on mortality and long-term survival, careful postoperative management and proper informed consent to patients with renal dysfunction are needed.
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